Results 131 to 140 of about 35,534 (303)

Regulation of MYCN expression in human neuroblastoma cells

BMC Cancer, 2009
Background Amplification of the MYCN gene in neuroblastoma (NB) is associated with a poor prognosis. However, MYCN-amplification does not automatically result in higher expression of MYCN in children with NB.
de Vries I, Hulsbergen-van de Kaa Christina A, van Leeuwen Frank N, van Bokhoven Hans, Jacobs Joannes FM, Adema Gosse J, Hoogerbrugge Peter M, de Brouwer Arjan PM   +7 more
doaj   +1 more source

Multiple mechanisms disrupt the let-7 microRNA family in neuroblastoma [PDF]

, 2015
Poor prognosis in neuroblastoma is associated with genetic amplification of MYCN. MYCN is itself a target of let-7, a tumour suppressor family of microRNAs implicated in numerous cancers.
A Beckers, A Urbach, AD Bosson, AM Gurtan, Areum Han, B Boyerinas, BB Madison, BL Thériault, BP Lewis, C Mayr, C Mayr, C Melton, Catherine S. Spina, CJ Breen, CM Croce, CS Hackett, D Kim, D Rakheja, Daniel S. Pearson, DE Rushlow, DP Bartel, FA Karreth, Frank Berthold, Frederik Roels, G Barone, G Blandino, George Q. Daley, GM Brodeur, Grace S. LaPier, HC Tu, Ho-Chou Tu, HR Chiang, I Bray, J Lu, J Thiessen, James J. Collins, Jessica Theißen, Jihan K. Osborne, JJ Molenaar, JJ Molenaar, JM Maris, JM Maris, JM Maris, John T. Powers, K Ejeskär, Kaloyan M. Tsanov, KJ Baeyens, Kyle C. Kurek, L Poliseno, LH Nguyen, M Cesana, M Hafner, Marc Seligson, Marcella Cesana, NE Sanjana, O Shalem, Patrick Cahan, R Denzler, R Iwakawa, R Spitz, RC Seeger, Richard Ebright, S Iwasaki, S Roush, Samantha J. Ross, SJ Diskin, SM Johnson, SR Viswanathan, SR Viswanathan, TJ Pugh, TJ Pugh, U Ala, VB Sampson, WJ Kent, Y Tay, Yvanka de Soysa   +75 more
core   +2 more sources

Molecular alterations in high‐grade neuroendocrine tumors of the small intestine

The Journal of Pathology, Volume 268, Issue 2, Page 215-226, February 2026.
Abstract High‐grade neuroendocrine tumors of the small intestine are separated into two groups: well‐differentiated neuroendocrine tumors (NETs, high‐grade) and poorly differentiated neuroendocrine carcinomas (NECs). They represent very rare entities, with few molecular data available, and are very challenging to treat.
Agathe Hercent, Julien Masliah‐Planchon, David Cohen, Remy Nicolle, Jean‐Yves Scoazec, Philippe Ruszniewski, Ivan Bièche, Louis de Mestier, Anne Couvelard, Jerome Cros   +9 more
wiley   +1 more source

Editorial: Targeting MYCN in Pediatric Cancers [PDF]

Frontiers in Oncology, 2015
MYCN is the product of a gene frequently deregulated in childhood tumors that belongs to a small but very famous family of transcription factors whose prototype member is c-MYC. The other member of the family is L-MYC, identified as a gene amplified in a subset of lung cancers.
openaire   +4 more sources

Evaluation of Norepinephrine Transporter Expression and Metaiodobenzylguanidine Avidity in Neuroblastoma: A Report from the Childrens Oncology Group. [PDF]

, 2012
Purpose. (123)I-metaiodobenzylguanidine (MIBG) is used for the diagnostic evaluation of neuroblastoma. We evaluated the relationship between norepinephrine transporter (NET) expression and clinical MIBG uptake. Methods. Quantitative reverse transcription
Attiyeh, Edward, Baker, David, Batra, Vandana, Dubois, Steven, Geier, Ethan, Giacomini, Kathleen, Hogarty, Michael, Kreissman, Susan, London, Wendy, Maris, John, Martinez, Daniel, Matthay, Katherine, Naranjo, Arlene, Neuhaus, John, Pawel, Bruce, Segal, Mark, Yanik, Greg, Yee, Sook   +17 more
core   +2 more sources

Genomic Profiling of Pediatric Solid Tumors With a Dual DNA/RNA Panel: JCCG‐TOP2 Study

Cancer Science, Volume 117, Issue 2, Page 522-535, February 2026.
In the JCCG‐TOP2 nationwide pediatric cancer genomic profiling study, 204 patients' tumors and peripheral blood from 50 institutions across Japan were successfully analyzed using a dual DNA/RNA panel. A total of 147 (72%) had potentially actionable findings, including diagnostic, prognostic, and therapeutic findings in 111 (54%), 61 (30%), and 64 (31%),
Kayoko Tao, Takako Yoshioka, Miho Kato, Kazuyuki Komatsu, Shinichi Tsujimoto, Kenichi Sakamoto, Kazuki Tanimura, Minako Sugiyama, Masahiro Sekiguchi, Yoshiko Nakano, Yoshihiro Otani, Yasushi Yatabe, Akihiko Yoshida, Hajime Okita, Junko Hirato, Kenichi Kohashi, Yukichi Tanaka, Shinji Kohsaka, Takashi Kubo, Kuniko Sunami, Makoto Hirata, Shuichi Tsutsumi, Hiroyuki Aburatani, Katsuyoshi Koh, Masahiro Hirayama, Shuhei Karakawa, Yukayo Terashita, Hiroyuki Fujisaki, Takeshi Yagi, Akihiro Yoneda, Shinji Mochizuki, Hiroyuki Shichino, Tatsuya Suzuki, Tetsuya Takimoto, Koichi Ichimura, Chitose Ogawa, Kimikazu Matsumoto, Hitoshi Ichikawa, Motohiro Kato   +38 more
wiley   +1 more source

Regulation der Genexpression von MYCN in humanen Neuoblastomzellen durch Transkriptionsfaktoren der E2F-Familie [PDF]

, 2005
Seit fast 30 Jahren ist bekannt, dass die Amplifikation und Expression des Onkogens MYCN in Neuroblastomen mit einer sehr ungünstigen Prognose für die Patienten einhergeht.
Eilers, Martin (Prof. Dr.), Kneppe, Verena   +1 more
core   +1 more source

A pilot study of chemoimmunotherapy in the postconsolidation setting for high‐risk neuroblastoma (ANBL19P1): A report from the Children’s Oncology Group

Cancer, Volume 132, Issue 2, 15 January 2026.
Abstract Background Survival for patients with high‐risk neuroblastoma remains poor despite current‐era multimodality treatment that includes postconsolidation GD2‐directed immunotherapy. Given the promising responses in patients who receive dinutuximab‐based chemoimmunotherapy in the relapsed setting, the Children’s Oncology Group ANBL19P1 study ...
Ami V. Desai, Arlene Naranjo, Brian LaBarre, Lulu Chen, Kelly C. Goldsmith, Meaghan P. Granger, Lisa States, Sean G. Green, Mariel Trunzo, Wendy Fitzgerald, Steven G. DuBois, Rochelle Bagatell, Julie R. Park, Araz Marachelian   +13 more
wiley   +1 more source

MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma

Oncotarget, 2018
The MYC oncogenes and p53 have opposing yet interrelated roles in normal development and tumorigenesis. How MYCN expression alters the biology and clinical responsiveness of pediatric neuroblastoma remains poorly defined. Neuroblastoma is p53 wild type at diagnosis and repression of p53 signaling is required for tumorigenesis.
Agarwal, Saurabh, Milazzo, Giorgio, Rajapakshe, Kimal, Bernardi, Ronald, Chen, Zaowen, Barberi, Eveline, Koster, Jan, Perini, Giovanni, Coarfa, Cristian, Shohet, Jason M.   +9 more
openaire   +4 more sources

Correlation Between MYCN Gene Status and MYCN Protein Expression in Neuroblastoma: A Pilot Study To Propose the Use of MYCN Immunohistochemistry in Limited-Resource Areas

Journal of Global Oncology, 2019
PURPOSE: The most significant adverse risk factor for neuroblastoma (NB) is MYCN gene amplification, which strongly associates with high-risk disease.
Teresa Santiago, Nidale Tarek, Fouad Boulos, Caleb Hayes, Sima Jeha, Susana Raimondi, Carlos Rodriguez-Galindo   +6 more
doaj   +1 more source